Compare Pfizer Inc (PFE) vs SAP SE (SAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs SAP SE — how do they compare? Pfizer Inc trades at $27.77 (market cap $159.59B), while SAP SE trades at $213.95 (market cap $243.69B). The key difference: SAP SE is the larger of the two by market cap, and Pfizer Inc pays the higher dividend (6.14%). Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and SAP SE for 118 Days on average.
| PFE | SAP | |
|---|---|---|
Market Cap | $159.59B | $243.69B |
Volume | 30,937,010 | 1,991,579 |
Sector | Health | Technology |
52-Week High | $29.02 | $280.46 |
52-Week Low | $23.67 | $146.38 |
Typical Hold Time | 158 Days | 118 Days |
Enterprise Value | $211.09B | $242.43B |
Dividend Yield | 6.14% | 1.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
SAP trades at $212.40, up 0.92% with a bullish technical signal. The company reported strong Q1 2026 earnings beat but missed Q2 expectations. Revenue grew to $36.8B in 2025 with robust 20.41% net margin. Analyst consensus is bullish with $241.80 price target, though recent news shows mixed sentiment about AI execution and competitive threats.
SAP presents a compelling growth story with strong cloud revenue momentum and AI integration, though execution risks and valuation concerns remain. The stock offers 14% upside to consensus target, supported by €10B buyback program through 2027. Key risks include ERP market competition and margin pressure from cloud transition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About SAP SE
Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.
Read more on SAP →
